Anges to develop coronavirus vaccine with Osaka University

TOKYO (Reuters) – Japanese biopharmaceutical firm Anges inc said on Thursday it would join hands with Osaka University to develop a coronavirus vaccine.

Shares of Anges were up more than 12% after the announcement.

There are now over 93,000 cases globally according to a Reuters tally, with 13% or almost 12,700 cases in countries outside China, including in Japan.

Reporting by Chris Gallagher; Editing by Shri Navaratnam

Source: © 2019 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.

Follow us:
Visited 12 times